Comments Off on Alumis files for IPO to support work on oral TYK2 blockers
Comments Off on Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D
Comments Off on Inscripta Acquires Infinome Biosciences, Sestina Bio
Comments Off on BIOS Builders Interview with Mark Chao, Co-founder & CEO at TenSixteen Bio
Comments Off on Foresite Labs’ new $173M fund to bankroll fewer startups but ‘big ideas’ fueled by data
Comments Off on Foresite Capital Launches $173M Fund to Support Incubated Companies
Comments Off on TenSixteen Bio Plumbs Somatic Mosaicism for Source of Multiple Diseases
Comments Off on TenSixteen targets dynamic genome to find driver mutations, catch cancer earlier
Comments Off on Foresite and GV pour $40M into startup’s move to CHIP into new disease biology
Comments Off on With Forty Seven co-founder at the helm, new biotech spinout launches to target mutations potentially linked to numerous diseases